BamSEC and AlphaSense Join Forces
Learn More

Ligand Pharmaceuticals Incorporated

NASDAQ: LGND    
Share price (12/20/24): $114.64    
Market cap (12/20/24): $2.166 billion
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 10-Q 74 pages This Agreement on the Acquisition of Stocks in Apeiron Biologics AG ("Agreement") Is Entered on 15 June 2024 by and Between 1. Ligand Pharmaceuticals Incorporated 3911 Sorrento Valley Boulevard, Suite 110, San Diego, Ca, United States of America
12/34/56
EX-2.4
from 8-K 14 pages Amended and Restated Forward Purchase Agreement
12/34/56
EX-2.3
from 8-K 9 pages Avista Public Acquisition Corp. II 65 East 55th Street, 18th Floor New York, Ny 10022 Re: Letter Agreement Ladies and Gentlemen
12/34/56
EX-2.2
from 8-K 70 pages Separation and Distribution Agreement by and Among Ligand Pharmaceuticals Incorporated, Omniab, Inc. and Avista Public Acquisition Corp. II Dated as of March 23, 2022
12/34/56
EX-2.1
from 8-K 378 pages Agreement and Plan of Merger Dated as of March 23, 2022 by and Among Ligand Pharmaceuticals Incorporated, Omniab, Inc., Avista Public Acquisition Corp. II and Orwell Merger Sub Inc. -I
12/34/56
EX-2.5
from 10-Q 14 pages Contingent Value Rights Agreement
12/34/56
EX-2.1
from 8-K 115 pages Clause Page
12/34/56
EX-2.1
from 8-K 106 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated, Pelican Acquisition Sub, Inc. and Pfenex Inc. Dated as of August 10, 2020
12/34/56
EX-2.1
from SC TO-C 106 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated, Pelican Acquisition Sub, Inc. and Pfenex Inc. Dated as of August 10, 2020
12/34/56
EX-2.1
from 10-Q 80 pages Asset Purchase Agreement by and Between Icagen, Inc. Certain Subsidiaries of Icagen Inc. and Adjacent Acquisition Co., LLC February 11, 2020
12/34/56
EX-2.1
from 8-K 21 pages Asset Purchase Agreement by and Between Ligand Pharmaceuticals Incorporated and Rpi Finance Trust Dated as of March 5, 2019
12/34/56
EX-2.1
from 8-K ~50 pages Recommended Cash Offer for Vernalis PLC by Ligand Holdings Uk Ltd
12/34/56
EX-2.1
from 8-K 89 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated, Eagle Acquisition, Inc., Crystal Bioscience, Inc., and Shareholder Representative Services LLC as Shareholders’ Representative Dated as of October 4, 2017
12/34/56
EX-2.1
from 8-K/A 1 page Consent of Independent Registered Public Accounting Firm
12/34/56
EX-2.1
from 8-K >50 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated, Schrader 1 Acquisition, Inc., Schrader 2 Acquisition, Inc., Open Monoclonal Technology, Inc., Omt, LLC and With Respect to Sections 2.14 and 6.6 and Article VIII Only Fortis Advisors LLC as Stockholders’ Representative Dated as of December 17, 2015
12/34/56
EX-2.1
from 8-K 1 page Certificate of Merger of Caymus Acquisition, Inc. (A Delaware Corporation) With and Into Cydex Pharmaceuticals, Inc. (A Delaware Corporation) Pursuant to Section 251 of the General Corporation Law of the State of Delaware
12/34/56
EX-2.1
from 8-K 2 pages Certificate of Merger of Moonstone Acquisition, Inc. (A Delaware Corporation) With and Into Metabasis Therapeutics, Inc. (A Delaware Corporation) Pursuant to Section 251 of the General Corporation Law of the State of Delaware
12/34/56
EX-2.1
from 8-K 2 pages Certificate of Merger of Neon Signal, LLC (A Delaware Limited Liability Company) With and Into Neurogen Corporation (A Delaware Corporation) Pursuant to Section 264 of the General Corporation Law of the State of Delaware
12/34/56
EX-2.1
from 8-K 68 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated, Margaux Acquisition Corp., Latour Acquisition, LLC and Pharmacopeia, Inc. Dated as of September 24, 2008
12/34/56
EX-2.1
from 425 68 pages Agreement and Plan of Merger by and Among Ligand Pharmaceuticals Incorporated, Margaux Acquisition Corp., Latour Acquisition, LLC and Pharmacopeia, Inc. Dated as of September 24, 2008
12/34/56